Details for Patent: 9,238,070
✉ Email this page to a colleague
Title: | Therapies for hematologic malignancies |
Abstract: | The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, ##STR00001## wherein R is H, halo, or C1-C6 alkyl; R' is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient. |
Inventor(s): | Gallatin; W. Michael (Mercer Island, WA), Ulrich; Roger G. (Seattle, WA), Giese; Neill A. (San Francisco, CA) |
Assignee: | Gilead Calistoga LLC (Foster City, CA) |
Filing Date: | Feb 07, 2013 |
Application Number: | 13/762,238 |
Claims: | 1. A method for treating a hematological malignancy in a subject in need thereof, comprising administering a compound of formula I'' ##STR00017## or a pharmaceutically acceptable salt thereof, and bortezomib. 2. The method according to claim 1, wherein said hematological malignancy is leukemia or lymphoma. 3. The method according to claim 1, wherein said hematological malignancy is selected from the group consisting of mantle cell lymphoma (MCL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), small lymphocytic lymphoma (SLL), follicular lymphoma, Waldenstrom's macroglobulinemia (WM), and B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL). 4. The method according to claim 1, wherein the subject is refractory to chemotherapy treatment or is in relapse after treatment with chemotherapy. 5. The method according to claim 1, further comprising administering at least one additional therapeutic agent. 6. The method according to claim 1, comprising administering to said subject a pharmaceutical composition comprising the compound of formula I'' or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. 7. The method according to claim 1, wherein said subject has at least one enlarged lymph node. 8. The method according to claim 4, wherein said subject is refractory to at least two standard or experimental chemotherapy treatments. 9. The method according to claim 1, wherein said compound of formula I'' or a pharmaceutically acceptable salt thereof is administered at a dose of 50-350 mg BID. 10. The method according to claim 9, wherein said compound of formula I'' or a pharmaceutically acceptable salt thereof is administered at a dose of 150 mg BID. |